Synopsis of the 2017 U.S. Department of veterans affairs/ U.S. Department of defense clinical practice guideline: Management of type 2 diabetes mellitus

Paul R. Conlin, Jeffrey Colburn, David Aron, Rose Mary Pries, Mark P. Tschanz, Leonard Pogach*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

80 Scopus citations

Abstract

Description: In April 2017, the U.S. Department of Veterans Affairs (VA) and the U.S. Department of Defense (DoD) approved a joint clinical practice guideline for the management of type 2 diabetes mellitus. Methods: The VA/DoD Evidence-Based Practice Work Group convened a joint VA/DoD guideline development effort that included a multidisciplinary panel of practicing clinician stakeholders and conformed to the Institute of Medicine's tenets for trustworthy clinical practice guidelines. The guideline panel developed key questions in collaboration with the ECRI Institute, which systematically searched and evaluated the literature through June 2016, developed an algorithm, and rated recommendations by using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Recommendations: This synopsis summarizes key features of the guideline in 7 areas: patient-centered care and shared decision making, glycemic biomarkers, hemoglobin A1c target ranges, individualized treatment plans, outpatient pharmacologic treatment, glucose targets for critically ill patients, and treatment of hospitalized patients.

Original languageEnglish
Pages (from-to)655-663
Number of pages9
JournalAnnals of Internal Medicine
Volume167
Issue number9
DOIs
StatePublished - 7 Nov 2017
Externally publishedYes

Fingerprint

Dive into the research topics of 'Synopsis of the 2017 U.S. Department of veterans affairs/ U.S. Department of defense clinical practice guideline: Management of type 2 diabetes mellitus'. Together they form a unique fingerprint.

Cite this